Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 13, 2015 1:20 PM ET

Life Sciences Tools and Services

Company Overview of Cancer Research Technology Limited

Company Overview

Cancer Research Technology Limited operates as a cancer-focused drug discovery, technology transfer, and commercialization company. It develops and licenses oncology related opportunities with pharmaceutical and biotechnology companies; and translates academic discoveries into industrial propositions. The company engages in sourcing and developing cancer discoveries; providing technology transfer services to cancer researchers; and identifying scientific and business solutions to unmet needs in cancer. Its drug discovery programs include the identification of small molecule inhibitors against various target classes, including kinases, kinesins, methyltransferases, and molecular chaperone tar...

Angel Building

407 St John Street

London,  EC1V 4AD

United Kingdom

Founded in 1982


44 20 3469 6300


44 20 3014 8633

Key Executives for Cancer Research Technology Limited

Chief Executive Officer and Director
Chief Operating Officer and Chief Executive of Cancer Research UK
Head of Medicinal Chemistry
Head of Molecular Pharmacology, Biochemistry & High Throughput Screening
Head of Clinical Partnerships
Compensation as of Fiscal Year 2015.

Cancer Research Technology Limited Key Developments

Cancer Research Technology Limited Presents at 15th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2015 12:00 PM

Cancer Research Technology Limited Presents at 15th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2015 12:00 PM. Venue: Congress Center, Basel, Switzerland. Speakers: Clive Stanway, Chief Scientific Officer, Director of Technology Development and Director.

EpiStem Holdings Plc Announces the Signing of a Licensing Agreement with Cancer Research Technologies and Newcastle University

Epistem Holdings Plc announced the signing of a licensing agreement with Cancer Research Technologies (CRT) and Newcastle University for access to and development of patient derived Acute Lymphoblastic Leukemia (ALL) Primagraft samples for commercial use. This agreement builds upon Epistems expertise with cell line based disseminated models of leukemia, and will further enhance the Company's ability to support pre-clinical therapeutic evaluation in haematological disease. The licensed Primagraft models include a range of fully cytogenetically characterized samples, with complete clinical history. In addition to FACs based methodologies, several of these systemic Primagraft models have been stably lentivirally transduced with a luciferase vector allowing monitoring of in-life treatment responses and evaluation of disease severity using Epistems Bruker In Vivo Xtreme Optical imaging system.

Medivir AB and Cancer Research Technology Collaborate to Develop New Class of Cancer Drugs

Medivir AB and Cancer Research Technology jointly announced a partnership to develop a new class of drugs that has shown promise for treating a range of different cancers, including pancreatic cancer. As part of the collaboration, CRT and Medivir will conduct a two-year research programme to optimize and develop small molecules targeting the cell surface protein ADAM8, which has been linked to tumour survival, cell invasion and metastasis. Under the terms of the agreement Medivir receives an exclusive, global license to research, develop, manufacture and commercialize ADAM8 inhibitor drugs resulting from development. CRT receives an upfront payment and future milestones as well as royalties on sales which are shared with the academic collaborators. Blocking ADAM8 in mice with pancreatic cancer prevented the spread of the disease, shrunk tumours and significantly extended lifespan. This is thought to be due to its involvement in cell adhesion, cell migration, inflammation and the growth of blood vessels – key processes that many cancers rely on for growth and development. High levels of the protein have been linked with more aggressive tumours including those in pancreatic, breast, brain, prostate, lung, head and neck, and kidney cancers. This research will be led by Professor Jörg Bartsch as head of the TransMIT-Project Division for Research in Neuro-Oncology at TransMIT GmbH, located at Marburg University in Germany, in collaboration with Medivir. Prof. Bartsch previously worked at King’s College London where the initial patent application was filed by King’s College IP and Licensing team. Further proof of concept studies were funded by Cancer Research UK at King’s College.

Similar Private Companies By Industry

Company Name Region
deltaDOT Ltd. Europe
Sequani Limited Europe
i3 Research Limited Europe
Cytomos Limited Europe
Onco-NX Ltd Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cancer Research Technology Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at